#
- 503A bulks list
- The list, made by FDA regulation, of bulk substances without a monograph or an approved drug that may be used in section 503A compounding.
A
- Acetate salt
- The acetate salt form of a peptide, made by exchanging the trifluoroacetate counter-ion left by synthesis and purification.
- Adequate directions for use
- Directions under which a layman can use a drug safely and for its intended purposes; a drug without them is misbranded.
- Aggregation
- The association of peptide molecules into larger assemblies, from soluble oligomers to visible particles.
- Aliquot
- A measured portion of a solution set aside in its own tube, so that the rest is never warmed, opened or refrozen on its account.
- Amino acid analysis
- Hydrolyzing a peptide to its amino acids and quantifying each, to confirm composition and measure peptide content.
- Aspartimide
- A ring formed at an aspartic acid residue during synthesis or storage, which re-opens to give same-mass variants of the peptide.
B
- Bacteriostatic water
- Purified water, or 0.9% sodium chloride, with 0.9% benzyl alcohol added as an antimicrobial preservative, sold as a laboratory reagent.
- Buffer
- A solution of a weak acid and its conjugate base that holds pH nearly constant when small amounts of acid or base are added.
C
- C-terminal amide
- A peptide end in which the final carboxylic acid is replaced by a carboxamide (–CONH₂), removing its negative charge.
- C18 column
- An HPLC column packed with silica particles bonded to 18-carbon alkyl chains, the standard stationary phase for reversed-phase peptide analysis.
- CAS Registry Number
- A unique numeric identifier assigned to a chemical substance by the Chemical Abstracts Service.
- Certificate of analysis
- A document reporting the tests performed on one specific lot of a material, with their methods and results.
- Chromatographic purity
- The share of the total UV peak area in an HPLC chromatogram that belongs to the main peak, reported as a percentage.
- Compounded drug
- The preparation of a drug by a licensed pharmacist or physician for an identified individual, exempt from FDA approval only under the conditions of section 503A or 503B.
- Counter-ion
- An ion of opposite charge that accompanies a charged peptide in the solid, such as trifluoroacetate, acetate or chloride.
- Cyclic peptide
- A peptide whose chain is closed into a ring, through its backbone ends, its side chains or a disulfide bond.
D
- D-amino acid
- The mirror-image form of an amino acid; natural proteins are built almost entirely from the L forms.
- Deamidation
- A degradation reaction in which an asparagine or glutamine side-chain amide is hydrolyzed to an acid, adding about 1 Da.
- Deletion sequence
- A synthesis impurity missing one residue of the intended sequence, formed when a coupling fails on some chains and the next succeeds.
- Disulfide bond
- A covalent S–S link between the side chains of two cysteine residues.
- DMSO
- A polar aprotic solvent that dissolves nearly every peptide, used for concentrated stocks that are then diluted into aqueous buffer.
E
- Endotoxin
- Lipopolysaccharide from the outer membrane of Gram-negative bacteria, measured because it can confound cell-based in vitro assays.
- Enforcement discretion
- An agency's statement that it will not enforce a requirement in stated circumstances, which leaves the requirement in place and binds no one.
F
- FDA Category 2
- The three groups in FDA's interim 503A policy for nominated bulk substances: under evaluation (1), raising significant safety risks (2), and nominated without adequate support (3).
H
- HPLC
- High-performance liquid chromatography: separates the components of a sample by how strongly each is held by a packed column, and measures each as it elutes.
- Hygroscopic
- Readily taking up water from the air; most lyophilized peptides are hygroscopic.
I
- Import alert
- An FDA notice that allows shipments of specified products or firms to be detained at the border without physical examination.
- In vitro
- Latin for "in glass": experiments carried out with cells, tissues or molecules outside a living organism.
- Intended use
- The purpose for which a seller intends a product, judged objectively from its statements, the product itself and the circumstances in which it is sold.
- Isoelectric point
- The pH at which a peptide carries no net charge; solubility is usually lowest near it.
K
- Karl Fischer titration
- A titration specific to water, used to measure the water content of a solid such as a lyophilized peptide.
L
- Lot traceability
- The ability to trace a unit of material back to its lot, and that lot to its testing, receipt and every place it went.
- Lyophilization
- Freeze-drying: removing water from a frozen solution by sublimation under vacuum, leaving a dry solid.
M
- Mass spectrometry
- An analytical technique that ionizes molecules and measures their mass-to-charge ratio, used to confirm a peptide's identity from its molecular mass.
- Medicinal product by presentation
- The European and British definition of a medicine: a substance presented as having properties for disease, or one that may be used to modify a physiological function.
- Methionine oxidation
- Oxidation of methionine to methionine sulfoxide (+16 Da), the most common oxidative change in peptides.
- Molarity
- The concentration of a solution in moles of solute per liter, written M, mM, µM or nM; for a peptide it is mass concentration divided by molecular weight.
- Molecular weight
- The mass of a molecule; for peptides, either the monoisotopic mass (most abundant isotopes only) or the average mass (natural isotope distribution).
N
- N-terminal acetylation
- Capping a peptide's free N-terminal amine with an acetyl group, which removes its positive charge.
- Net peptide content
- The fraction of a weighed peptide powder that is the peptide itself, the rest being counter-ions, bound water and residual solvent.
O
- Outsourcing facility
- A compounding operation registered with FDA under section 503B, held to current good manufacturing practice and inspected by FDA on a risk-based schedule.
P
- Peptide bond
- The amide bond joining the carboxyl group of one amino acid to the amino group of the next.
- Poisons Standard
- Australia's schedule of substances, which controls possession and supply of a named substance regardless of how it is labeled or sold.
- Protecting group
- A chemical group attached to a reactive part of an amino acid during synthesis, so that only the intended bond forms, and removed afterward.
R
- Racemization
- The conversion of an amino acid residue from one mirror-image form to the other, which in a peptide gives a diastereomer of the same mass.
- Related substances
- The peptide-related impurities in a sample, such as deletion sequences, oxidized or deamidated forms and diastereomers, reported individually by HPLC.
- Research use only
- A labeling category for materials sold for laboratory research and not for human or veterinary use, diagnostics or any clinical purpose.
- Responsible corporate officer doctrine
- The rule that corporate officers in a position to prevent or correct a violation of the drug law can be criminally liable without proof that they took part in it.
- Retention time
- The time from the start of an HPLC run, when the sample is loaded onto the column, to the top of a component's peak.
S
- Serial dilution
- A chain of dilutions, each made from the previous one, used to reach a large dilution factor in pipettable steps.
- Solid-phase peptide synthesis
- The standard way peptides are made: amino acids added one at a time to a chain anchored on an insoluble resin.
- Stock solution
- A concentrated solution of known concentration, made once and diluted to working concentrations as needed.
T
- Tandem mass spectrometry
- Mass spectrometry in two stages: one ion is selected and broken apart, and its fragments are weighed, to read out a peptide's sequence.
- TFA salt
- The trifluoroacetate salt form of a peptide, the usual form after cleavage and reversed-phase purification with trifluoroacetic acid.
U
- Unapproved new drug
- A drug that is not generally recognized as safe and effective for its labeled uses and has no approved application, which may not be sold in interstate commerce.
W
- Warning letter
- FDA's written notice to a company that it considers the company to be in significant violation of the law, with a demand for correction.
Changes to this page
- Updated Five glossary terms for compounding
Compounded drug, the 503A bulks list, FDA's interim bulk-substance categories (Category 1, 2 and 3), outsourcing facility and enforcement discretion: the terms the United States series' compounding pages rely on, each linked where it first appears in the library.
- Updated How research peptides are regulated around the world
The first page of a series on research peptides outside the United States: the four questions every system answers, the United States, United Kingdom, European Union, Canada and Australia side by side, sport and the source, and what is the same everywhere. The timeline gains the MHRA investigation, Health Canada's seizures, advisory and injunction, and the TGA alerts; the glossary gains medicinal product by presentation, the Poisons Standard and import alert.
- Updated Solutions and laboratory arithmetic: ten methods articles
Preparing peptide solutions, with nine articles on the arithmetic and chemistry behind it: molarity, concentration units, stock solutions and serial dilutions, weighing milligrams, which solvent for which peptide, why a peptide will not dissolve, pH, buffers and charge, bacteriostatic water and saline as reagents, and storing solutions; with seven new glossary terms.
- Published The research library opens
HPLC purity analysis, a glossary of peptide chemistry and analysis, and the editorial policy.
Changes of substance are listed here; wording changes are not. Every correction is also on the corrections log.
For in vitro laboratory research only. Not for human or veterinary use. This library describes chemistry, analytical methods and published laboratory research; it gives no guidance on use in people or animals.